Alleviating Symptoms of Acute and Chronic Respiratory Diseases and Otitis Media.

From: Townsend Letter for Doctors and Patients  |  Date: 11/1/2005  |  Author: Mamber, Stephen W.; McMichael, John

Microdose DNA: Background, Product Description and Proposed Mechanisms of Action

Acute and chronic respiratory diseases, including common colds, allergic rhinitis, sinusitis, bronchitis, mucositis, asthma, emphysema, chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) as well as otitis media, have different etiologies. Causative agents include microorganisms (colds, otitis), environmental insults (asthma, COPD), cancer radiotherapy (mucositis), and gene mutation (CF). However, there are some clinical features common to all these diseases, including inflammation, bronchial and/or sinus congestion, obstructed airflow, and production of large amounts of sputum and/or nasal mucus. (1-15)

CF is an often-fatal genetic disorder of exocrine function characterized by abnormally viscous mucus secretions leading to chronic pulmonary obstruction, pancreatic insufficiency and elevated sweat sodium and chloride levels. (2,10,12,16) The viscosity of sputum produced by CF patients is believed to result from a high content (approximately 10% of the total sputum dry weight0 of DNA released from necrotic neutrophils in the sputum. (17-18) This has led to the use of DNase (Dornase alfa; Pulmozyme) as a CF therapy in conjunction with the antibiotics, bronchodilators and corticosteroids regularly used in the treatment of CF. (17-18)

The rationale for DNase therapy was that degrading DNA in sputum would reduce the viscosity of the sputum, resulting in an increased ability of the patient to evacuate sputum from the lungs and nasal passages. (17,18) Accordingly, it was hypothesized that mammalian DNA itself could be employed as a neutralization therapy in order to reduce the immune response to excessive DNA in CF patients. This became the basis for the development of a sublingually administered DNA-based therapeutic composed of a proprietary formulation of DNA fragments derived from eukaryotic vertebrate DNA. (19) It was hoped that in the case of CF, sublingual dosing with DNA would ultimately lead to decreased neutrophil necrosis and DNA release into the sputum in the lungs, which would in turn result in decreased sputum viscosity. Subsequently, it was found that this sublingual therapeutic approach had broader application to a variety of respiratory diseases as well as to the treatment of otitis media. (20-24)

Milkhaus Laboratory, Inc. developed the original product, named HP-3 or ML-03. The current DNA-based therapeutic, derived from salmon testicle DNA, is being sold commercially as Mucolyxir. It has been referred to as microdose DNA because it is administered in microgram-range doses. Mucolyxir is administered as single sublingual drops of about 50 ul. Reduced congestion, decreased mucus viscosity and/or decreased inflammation in the upper and lower airways leading to improved respiratory functions are common observations in patients treated with microdose DNA. Based on dosage (low-level) and administration route (sublingual), microdose DNA may promote or restore homeostasis within the respiratory tract to relieve disease symptoms by an as-yet uncharacterized signaling pathway(s) involving the body’s regulatory systems, notably (though not limited to) the immune system.

There have been several proposed hypotheses, discussed in detail elsewhere, (25) regarding mechanisms by which microdose DNA can alleviate various respiratory ailments. They can be summarized as follows:

1) Immunotherapy via Desensitization, Hyposensitization or Neutralization

2) Stimulation of Chloride Secretion and Improved Mucociliary Clearance via Interaction With P2 Nucleotide Receptors

3) Generation of Beneficial Immune Responses Through Changes in Ratios of Cytokines Involved in the Humoral and Cell-mediated Immune Response (Th1/Th2 Ratios)

4) Antiinflammatory Effects Such As Decreased Production of Proinflammatory Cytokines and/or Increased Production of Antiinflammatory Cytokines

5) Decreased Mucus Viscosity and Improved Mucociliary Clearance via Increased Production of Antiinflammatory Cytokine Interleukin-4

Clinical Experiences with Microdose DNA

Microdose DNA was active in three IND-based, double-blind, placebo-controlled, FDA-approved Phase II clinical trials for efficacy in the treatment of chronic bronchitis, chronic obstructive pulmonary disease (COPD) and cystic fibrosis. (25) In addition to these clinical trials, the utility of microdose DNA in alleviating the symptoms of various respiratory diseases, as well as that of otitis media, has been demonstrated through evidence-based clinical testing. What follows are examples of these clinical experiences, extracted from available patent literature. (19-24) All patients were treated under informed consent with sublingual drops of microdose DNA from either calf thymus or salmon sperm.

Cystic Fibrosis

In one of the earliest clinical experiences with microdose DNA, 23-year-old twin brothers presented with cystic fibrosis. Each had a history of hospitalizations for lung clearance and secondary infections diagnosed as being associated with their cystic fibrosis. Each patient began therapy with 1-2 drops of microdose DNA sublingually per day. Subsequent to initiating DNA therapy, follow-up evaluations of the twins were conducted for almost seven years. Neither patient was hospitalized during that time interval. Furthermore, physician evaluations revealed a 30-45% increase in airflow in each patient. Forced vital capacity, a common measure of lung capacity and the extent of mucus clearance in the lungs, increased from 60-90%. Also, each of the brothers gained weight and showed increased expectoration. Interestingly, after approximately one year of therapy, one twin stopped taking the DNA drops. His condition steadily worsened, with increased mucus viscosity, decreased forced vital capacity and reduced expectoration. That patient then began taking drops of DNA at the prescribed dose and rapidly improved to the condition he was in prior to the time at which he stopped taking the drops.

COPD

The following two patients suffered from mild to moderate COPD not characterized by aberrant mucous accumulation. The first subject was a 67 year-old male former smoker with a medical history of gout, hypertension, peptic ulcer and chronic obstructive pulmonary disease. He presented with shortness of breath during high humidity, walking up a half flight of stairs, walking in the yard and at night laying flat in bed. The subject suffered from minimal phlegm production, which was white in color. The subject was being treated with allopurinol, Pepcid (famotidine), Slobid (theophylline), Calan (verapamil HCl), Accupril (quanapril HCl) and Albuterol Inhaler. A pre-study office spirometry showed moderate COPD with an Fev1% of 51. The subject was treated with 1 drop of microdose DNA sublingually four times per day. After fourteen days of treatment, the subject reported that his overall dyspnea had improved from a subjective rating of a 10 to a 4. He was able to walk at the mall without shortness of breath where previously he had to stop. Spirometry on day 16 showed no change but three months later with continued treatment the patient could ascend 13 steps where prior to treatment he had been able to ascend only half as many steps without dyspnea. The subject was also able to decrease Albuterol administration from daily to 2-3 times weekly and eventually to once in four weeks and discontinue use of Slobid. The subject’s wife reported that the subject’s sleep was more restful and that she no longer heard wheezing at night.

The second patient was a 71 year-old female with a medical history of hypertension, myocardial infarction, renal insufficiency, hiatal hernia, spinal stenosis, hyperlipidemia and chronic obstructive pulmonary disease presented with shortness of breath while cooking meals, walking 17 steps, carrying laundry, vacuuming, making her bed, walking to the car, and in the mall. She also complained of minimal phlegm. She was undergoing treatment with medications including Cardizem CD (diltiazem HCl), Vasotec (enalaprilat), Zocor (simvastatin), Ogen (estropripate), Zantac (ranitidine HCl), Toprol (metoprolol succinate), Nitroglycerine patch, LorTab (hydrocodone bitartrate and aspirin), and a sleep agent as required. Upon examination, she had mild anterior wheezing and a pre-study office spirometry showed an Fev1 of 70. The subject was treated with 1 drop of microdose DNA sublingually four times per day. After seven days of treatment the subject reported no improvement, but after fourteen days of treatment, the patient reported that she could walk in the mall without shortness of breath and was vacuuming and making her bed without needing to stop and rest. A repeat spirometry after fourteen days showed an Fev1% of 78, an 11% improvement from the pre-study result. The subject’s condition continued to improve except when she decreased the treatment schedule to once per day and her shortness of breath returned. After increasing back to treatment four times daily her dyspnea resolved to the extent that she was able to discontinue her use of a Serevent (Glaxo) aerosol inhaler after four months.

Chronic Upper Respiratory Illness

A 25-year-old female was diagnosed with chronic upper respiratory illness. Previous antibiotic therapy was unsuccessful in treating her condition. She began with 1 drop of microdose DNA sublingually four times per day. Within one day, she experienced an increase in expectoration and, after three days she was able to discontinue treatment, having been completely relieved of congestion, and remained symptom free for an extended period of time.

Respiratory Congestion

A 37-year-old female presented with unresolved respiratory congestion. Conventional therapy, including expectorants, failed to improve her condition. The patient was then prescribed four sublingual drops of microdose DNA per day. After one day of treatment, her congestion was more productive and sinus drainage had begun where none was present prior to treatment. Also, a 40-year-old woman with unproductive upper respiratory congestion was placed on 4 drops of sublingual microdose DNA per day. Her congestion was more productive after one day and she continued to expectorate freely. In this instance, microdose DNA therapy was supplemented with an over-the-counter expectorant.

Respiratory Disease Resulting from Occupational/Environmental Chemical Exposure

The sublingual administration of one drop of microdose DNA provided almost immediate relief of symptoms of respiratory disorders caused by chemical or environmental sensitivities. The therapy was tested on at least a dozen individuals including children and adults and was successful in all these cases. As one example, a 38-year-old woman suffered from acute and chronic respiratory disease due to exposure to toxic corrosive materials. Symptoms, including chronic rhinorrhea, chest congestion and chronic respiratory infections were treated with numerous courses of antibiotics without success. The patient began treatment with sublingual microdose DNA drops four times daily and was instructed to administer treatment up to 5-6 times daily if necessary. Upon commencing treatment, the patient was able to produce sputum almost immediately. Continued treatment alleviated symptoms of chronic respiratory illness.

Asthma

Several asthma patients were treated by daily sublingual administration of at least one drop of microdose DNA. Follow-up evaluation of those subjects showed decreased viscosity and volume of sputum. For instance, a 54-year-old male presented who had suffered from asthma since childhood. This had resulted in restricted physical activity for years. The patient was treated by sublingual administration of microdose DNA with the result that the patient became able to run several miles daily and work without undue fatigue. Another asthmatic, a 5-year-old autistic female, was treated by sublingual administration of microdose DNA. This patient exhibited improved respiratory function on a day-to-day basis and was able to eliminate other asthma medications including inhalers.

Respiratory Allergies

The following two cases relate to the use of microdose DNA for treating respiratory allergies to various environmental agents. First, a 7-year-old male presented with a history of broad spectrum allergies to environmental inhalants and foods. He had been specifically treated for allergies in the past with limited success. Of particular interest in this case is that the patient was exposed to factory exhausts en route to school. On days with high humidity and “heavy” air, he was likely to almost immediately begin displaying hyperactive behavior, restlessness, flushing and incoherent speech. The subject was treated with sublingual administration of one drop of microdose DNA and was restored to his pre-exposure state within five minutes. Without administration of the therapeutic agent, the symptoms would continue to be exhibited by the patient for several hours. This pattern of response (with and without administration of the therapeutic agent) was repeated and observed more than two dozen times. In the second case, a 32-year-old female presented with sensitivity to several environmental inhalants such as road dust, hay and various pollens exposure which resulted in full sinuses, a throbbing headache, watery eyes and weakness. Sublingual administration of one drop of microdose DNA resulted in a decrease or elimination of symptoms within 15-20 minutes, although multiple doses were required if allergen exposure was severe.

Radiation-induced Mucositis

A subject suffering from radiation-induced mucositis was treated with one drop of microdose DNA sublingually four times per day. The subject experienced a 50% improvement with phlegm thickness and had less cough. Experimentation by the subject with dosage frequency revealed that administration of one drop alone was insufficient but that administration of three to four drops per day appeared to be optimal. Another subject using the same treatment regimen also reported a 50% improvement in phlegm thickness. In addition, this subject noted an improvement in sense of taste from nonexistent to normal.

Otitis Media

Although otitis media is not a respiratory disease per se, sublingual administration of microdose DNA was found to be useful in treatment of otitis media with rapid and reproducible responses. The following three cases are presented. Case one was that of a 5-year-old female who presented with severe recurrent otitis media in the right ear with bulging of the tympanic membrane. The subject was treated with sublingual administration of one drop of microdose DNA four times daily for seven days. When the subject was rechecked two days later the mother reported the child’s temperament and energy improved the first evening. She went to school the next day. On examination, she had an infected tympanic membrane, but the bulging was gone. Significantly, this subject had been treated for otitis media numerous times in the past with antibiotics. Roughly nine days after termination of treatment with microdose DNA, the subject developed recurrent pain in the left ear with a fever of 101 degrees F. Her mother did not contact the physician but administered microdose DNA again with success. She went to school the next day. The patient presented at a later date with recurrent otitis media in the right ear. She was again treated by sublingual administration of microdose DNA, resulting in a rapid sense of pain relief, temperature resolution and improved overall well-being.

Case two was that of a 9-year-old female who presented with a plugged feeling in the right ear, fever of 100 degrees F and minimal pain. A right otitis media was diagnosed. The subject was treated with sublingual administration of one drop of microdose DNA four times daily. The first night of treatment, the child slept well, the pain left and she went to school the next day. Four days later the redness and fluid were less. The mother reported that usually with otitis media and antibiotic treatment, her child had 2-3 restless nights and usually missed 2-3 days of school. In contrast, after treatment with microdose DNA the child was able to go to school the following day.

Case three was that of a 14-month-old male presenting with recurrent bilateral serous otitis media for which surgery to insert tympanostomy tubes into the Eustachian tubes was originally recommended. The subject was treated with sublingual administration of one drop of microdose DNA four times daily. Evaluation one and two months later revealed incomplete resolution of fluid, but evaluation three months later revealed complete elimination of fluid. Five months after initiation of therapy, bilateral otitis media recurred, but resumption of therapy with the DNA drops resulted in a complete resolution.

In addition to the above, beneficial clinical improvement from the use of microdose DNA has also been documented for emphysema, bronchitis, chronic upper respiratory illness, chronic sinusitis and acute upper respiratory infections. (19-24)

Microdose DNA As a Treatment For Symptoms of the Common Cold: Comparison With Echinacea

There have been no formal investigations of microdose DNA in alleviating cold symptoms. However, there have been numerous anecdotal reports that immediately upon the onset of cold symptoms, sublingual administration of one drop of microdose DNA 4-8 times daily for 5-10 days alleviates such cold symptoms as sore throat, congestion and excessive nasal discharge. (Some individuals have reportedly administered as much as one sublingual drop every hour at cold onset and then reduced the number of drops per day over the next several days). The reported ability of microdose DNA to control or relieve cold symptoms warrants a comparison with Echinacea, a popular herbal remedy used to relieve cold symptoms. (26-27) However, while Echinacea is widely used as a cold remedy, its effectiveness has been questioned in several formal clinical trials. (28-30) Echinacea has been categorized as a general immuno-stimulant, capable of inducing the production of various cytokines. (31-33)

While the precise mechanism(s) of action of microdose DNA require further elucidation, its effects appear to be directed toward decreased inflammation, reduced sputum viscosity, and improved mucociliary clearance within the respiratory tract. Furthermore, Echinacea is ingested in relatively large, milligram or even gram quantities as pills or other dosage forms. (26-30) In contrast, microdose DNA is administered with relative ease as 50 ul sublingual drops. Accordingly, if the reported effectiveness of microdose DNA in alleviating cold symptoms can be confirmed and extended through formal clinical investigations, microdose DNA could become a favored therapy for reducing the duration and intensity of common cold symptoms.

Correspondence:

John McMichael, PhD

The Institute for Therapeutic Discovery

P.O. Box 127Delanson, New York 12053 USA

Fax: 518-872-0753

References:

1. Bai TR, Knight DA. Structural changes in the airways in asthma: observations and consequences. Clin Sci (Lond). 2005 Jun;108(6):463-77.

2. Boucher RC. An overview of the pathogenesis of cystic fibrosis lung disease. Adv Drug Deliv Rev. 2002 Dec 5;54(11):1359-71.

3. Cole P. Pathophysiology and treatment of airway mucociliary clearance. A moving tale. Minerva Anestesiol. 2001 Apr;67(4):206-9.

4. Cowan MJ, Gladwin MT, Shelhamer JH. Disorders of ciliary motility. Am J Med Sci. 2001 Jan;321(1):3-10.

5. Epstein JB, Schubert MM. Oropharyngeal mucositis in cancer therapy. Review of pathogenesis, diagnosis, and management. Oncology (Williston Park). 2003 Dec;17(12):1767-79.

6. Galen BA. Chronic recurrent sinusitis. Recognition and treatment. Lippincotts Prim Care Pract. 1997 May-Jun;1(2):183-98.

7. Greenberg SB. Respiratory consequences of rhinovirus infection. Arch Intern Med. 2003 Feb 10;163(3):278-84.

8. Hogg JC. Chronic obstructive pulmonary disease: an overview of pathology and pathogenesis. Novartis Found Symp. 2001;234:4-19.

9. Houtmeyers E, Gosselink R, Gayan-Ramirez G, Decramer M. Regulation of mucociliary clearance in health and disease. Eur Respir J. 1999 May; 13(5):1177-88.

10. Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest. 2002 Mar;109(5):571-7.

11. Majima Y. Mucoactive medications and airway disease. Paediatr Respir Rev. 2002 Jun;3(2):104-9.

12. Robinson M, Bye PT. Mucociliary clearance in cystic fibrosis. Pediatr Pulmonol. 2002 Apr;33(4):293-306.

13. Rogers DF. Airway mucus hypersecretion in asthma: an undervalued pathology? Curr Opin Pharmacol. 2004 Jun;4(3):241-50.

14. Tiddens H, Silverman M, Bush A. The role of inflammation in airway disease: remodeling. Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 2):S7-S10.

15. West JV. Acute upper airway infections. Br Med Bull. 2002;61:215-30.

16. Morales MM, Capella MA, Lopes AG. Structure and function of the cystic fibrosis transmembrane conductance regulator. Braz J Med Biol Res. 1999 Aug;32(8):1021-8.

17. Bates RD, Nahata MC. Aerosolized dornase alpha (rhDNase) in cystic fibrosis. J Clin Pharm Ther. 1995 Dec;20(6):313-5.

18. Witt DM, Anderson L. Dornase alfa: a new option in the management of cystic fibrosis. Pharmacotherapy. 1996 Jan-Feb;16(1):40-8.

19. McMichael, J. Methods for treating respiratory disease. US Serial Number 5,726,160 (March 10, 1998).

20. McMichael, J, Allen, M, Treatment of otitis media by sublingual administration of DNA. US Serial Number 5,948,768 (September 7, 1999).

21. McMichael, J. Methods for treating respiratory disease. US Serial Number 5,955,442 (September 21, 1999).

22. McMichael, J. Method for treating mucositis by sublingual administration of DNA. US Serial Number 6,096,721 (August 1, 2000).

23. McMichael, J. Method for treating respiratory distress by sublingual administration of DNA. US Serial Number 6,100,244 (August 8, 2000).

24. McMichael, J. Treatment of symptoms of asthma and allergies. US Patent Application Number 20020115632 (August 22, 2002).

25. Mamber, SW, McMichael, J. Microdose DNA for the Treatment of Acute and Chronic Respiratory Diseases and Otitis Media. Journal of the American Nutraceutical Association, publication pending.

26. Giles JT, Palat CT 3rd, Chien SH, Chang ZG, Kennedy DT. Evaluation of echinacea for treatment of the common cold. Pharmacotherapy. 2000 Jun;20(6):690-7.

27. Melchart D, Linde K, Fischer P, Kaesmayr J. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev. 2000;(2):CD000530.

28. Barrett BP, Brown RL, Locken K, Maberry R, Bobula JA, D’Alessio D. Treatment of the common cold with unrefined echinacea. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002 Dec 17;137(12):939-46.

29. Yale SH, Liu K. Echinacea purpurea therapy for the treatment of the common cold: a randomized, double-blind, placebo-controlled clinical trial. Arch Intern Med. 2004 Jun 14;164(11):1237-41.

30. Turner RB, Bauer R, Woelkart K, Hulsey TC, Gangemi JD. An evaluation of Echinacea angustifolia in experimental rhinovirus infections. N Engl J Med. 2005 Jul 28;353(4):341-8.

31. Burger RA, Torres AR, Warren RP, Caldwell VD, Hughes BG. Echinacea-induced cytokine production by human macrophages. Int J Immunopharmacol. 1997 Jul;19(7):371-9.

32. Rininger JA, Kickner S, Chigurupati P, McLean A, Franck Z. Immunopharmacological activity of Echinacea preparations following simulated digestion on murine macrophages and human peripheral blood mononuclear cells. J Leukoc Biol. 2000 Oct;68(4):503-10.

33. Hwang SA, Dasgupta A, Actor JK. Cytokine production by non-adherent mouse splenocyte cultures to Echinacea extracts. Clin Chim Acta. 2004 May;343(1-2):161-6.

by Stephen W. Mamber, PhD, and John McMichael, PhD

COPYRIGHT 2005 The Townsend Letter Group
This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group.
For permission to reuse this article, contact Copyright Clearance Center.
http://www.encyclopedia.com/doc/1G1-138483342.html

Hi all.

We have been administering Mucolyxir to our 2 yr old for almost 2 weeks.
To date we have had remarkable progress and there seem to be no side effects. Prior to obtaining the Mucolyxir she was barely coughing up anything at all even when using the saline nebs yet we were getting no air entry in the left lung at all due to mucus plugging.
The effects of mucolyxir were almost immediate. The first day she had it she started coughing alot and each cough produced alot of sputum effortlessly. Over the next few days there was so much mucus coming up she sounded very chesty. The coughing has tapered down now but she is still producing sputum. We were reviewed last week and she is getting more air entry in the lung even from the week before and when doing chest physio her left side sounds alot more resonant than it did previously.
We have found Mucolyxir to be very beneficial for our daughter and it is so easy, just a few drops on the tongue and even our 2yr old puts her tongue out ready for her medicine!
Mucolyxir is really easy to order online at www.nutricology.com. It costs about US$35 per bottle (200 drops) which last approx 3wks to 1 mth plus shipping costs which was approx US $40 (pretty expensive for 2 bottles) and arrives on your doorstep in approx 1 week.
I have also tried to figure out how to get the article about Mucolyxir on to this website (apart from typing it!!) but havent quite worked that one out yet but if anybody can get a copy of the Health Sciences Institute booklet for October 2004 Vol 9 No.4 this article explains in more detail about the Mucolyxir discovery. Your doctor would probably have a copy otherwise email me and I can forward a copy to you. Email address is hallmark@xtra.co.nz
I hope that this info helps you

Annie
Joined: 20 Feb 2004
Posts: 6
Location: Hamilton
 Posted: Sun Dec 12, 2004 9:36 pm    Post subject:


[quote=”Annie”]Hi Esther,
Sounds as though things are going very well in your household.
Keep us informed of how the air entry is improving over time – would be keen to know more.
When was her last CXR, and when will she get another one?
Would be great to see a pre and post film, although this would be a little difficult, unless you can photograph these.
When do you see your chest physician again? Will be interesting to hear their thoughts.

 

Glad all is much better in such a short space of time,

Merry Christmas
Annie[/quote]

Hi Annie
Georgia’s last CXR was on 25/11 prior to us getting the Mucolyxir. It was still showing a complete white out of the left lower lobe with the right lung coming over slightly on to the left side. Starship are looking at doing another bronchoscopy in the next few weeks to do a whole lung lavage and try and flush out some of the mucus plugging the airways as some of them may be too big for her to cough out but they also wanted to give the Mucolyxir time to work aswell. My guess is that she will probably have another CXR one month after the bronchoscopy to see how things are going.
We will be seeing the paediatrician again on 20/12 for check up here locally and not quite sure when Starship want us back there for the bronchcoscopy.
We will definitely keep you guys informed.

Merry Xmas
Esther
Back to top
 
Patricia Chapman
 Posted: Sun Jan 30, 2005 9:20 pm    Post subject: Esther, Mucolyxir update ?


Hi Esther.
My name is Patricia. I spoke to a mother of 2 CF children in their late teens and she is using Mucolyxir with apparent great success. I am curious how your daughter is doing. How is her lung function since you last posted?

 

I have a 14.5 year old son with CF. I’m looking into ways I can help him increase lung function. I’m looking forward to your response.

Sincerely,
esther bonne

Joined: 15 Nov 2004
Posts: 7
Location: Ohope Beach
 Posted: Mon Jan 31, 2005 11:26 am    Post subject: Latest update on Mucolyxir use – 31 January 05


Hi there,

 

Just thought I would update the forum about our daughters progress with Mucolyxir since the last time.

In the last update, Georgia had just started using Mucolyxir and was coughing up a storm which was good news for us as prior to this nothing (not even saline nebs) were making her cough the sputum up.
A repeat bronchoscopy on 27 Dec 04 showed all airways were now clear of mucus, open and not inflamed. The specialist at Starship was very surprised as before the bronchoscopy she wasnt very confident that any good could be done for Georgia based on the infection she had and that she wasnt able to cough anything up.
A lavage was performed aswell and they managed to get a little bit of mucus but not a large amount.
A second bronchoscopy was performed last week aswell as CT and bronchiogram. A 2ml catheter was inserted into the scope to allow the specialist to go down further into the lung (6th, 7th and 8th generation airways) and as far as she could see the airways were open and not inflamed or scarred. CT showed everything normal apart from matting down of parenchyma tissue from the collapse. Bronchiogram showed dye going down airways but stopping around middle of lung. When anaethatist artificially ventilated lung with oxygen the lung inflated and allowed the dye to continue to run down into smaller airways.
This concluded that mucus plugging is no longer the problem as they initially thought but the lung tissue which has matted together from months of being collapsed. Georgia is now on a BIPAP machine to help reinflate the lung. We hope this will do the trick.
We continue to administer mucolyxir to Georgia to keep mucus production under control and since administering mucolyxir Georgia has been extremely well with no other complications, so well in fact she has been cleared by Starship to fly to the US in a few weeks to visit Disneyland.
Mucolyxir has been our saviour in clearing out her airways from all the mucus and pus which was toxic and that was our turning point. Without the clearance of mucus she wouldnt be so well in herself, probably would have suffered numerous reinfections and incurred serious damage and scarring to airways which havent occurred. Even starship told us to expect that there will be damage and scarring considering the length of time she has been like this and were very surprised at the outcome of the bronchoscopy.
We have also been using homeopathic medicine to support the immune system and heal the lung tissue. Another couple of products we have imported from the US in Blessed Herbs Lung rejuvenator which decongests, soothes, expands and cleanses airways (all herbal) and the Lung Cleanse which we are currently using which helps repair tissue damage.
If anyone requires any further info please contact me at hallmark@xtra.co.nz
Cheers
Esther
http://www.cfnz.org.nz/forum/viewtopic.php?p=158&sid=0ed214afd659be136a9a9f2e7dd1e83f

Cheers Esther

Posted: Mon Jan 31, 2005 11:26 am    Post subject: Latest update on Mucolyxir use – 31 January 05 Cheers Esther

Posted: Sun Jan 30, 2005 9:20 pm    Post subject: Esther, Mucolyxir update ? Posted: Mon Jan 31, 2005 11:26 am    Post subject: Latest update on Mucolyxir use – 31 January 05 Cheers Esther

Mucolyxir®
Nanotech Nutrients®
(Hypoallergenic)

 

Description: Mucolyxir® is a DNA-based formulation, utilizing DNA from wild Pacific salmon, that supports respiratory health.* One method by which the body attempts to keep the lungs clear of mucus is to mount an immune response against the agent(s) causing the problem. When the attempts to eliminate foreign material fail, excessive DNA can build up from lysed white blood cells, resulting in viscous mucus. The small amount of DNA in Mucolyxir® may balance mucus levels via a regulatory mechanism.* Based on pre-clinical investigations and clinical trials, Mucolyxir® appears to support cilia motion, and liquification and elimination of mucoid substance.*

Suggested use:1 or 2 drops, placed in mouth slowly, then swallowed, one to four times per day, or as directed by a healthcare practitioner. To avoid dilution, do not eat or drink for 5 minutes after taking.
Additional Usage Notes: At the start of use, individuals may take more, as follows:
Day 1: Take 1 drop every fifteen minutes for one hour. Then take 1 drop every hour until bedtime.
Days 2 and 3: Take 1 drop after each meal and before bed (4 times total).
Day 4 and beyond: Maintain schedule or use only as needed.
Caution: Some individuals may experience increased mucus excretion with only 1 or 2 doses.

Caution: Some individuals may experience increased mucus excretion with only 1 or 2 doses.
Serving Size 1 drop
Servings per container 240
Amount per serving:
DNA
0.3 µg

Other ingredients: Purified water, sodium chloride, potassium sorbate, lactic acid.

Keep in a cool, dry place, tightly capped.
http://www.allergyresearchgroup.com/proddesc/products/mucolyxir.htm

Articles and Additional Information on Natural Microdose DNA (Mucolyxir)

Articles and Additional Information on Natural Microdose DNA (Mucolyxir)
Index:


Natural Microdose DNA (Mucolyxir) Use In:

Respiratory Diseases
Asthma
Allergic Rspiratory Disease
Allergic Rhinitis
Cystic Fibrosis
Sinusitis
Bronchitis
COPD
Emphysema
Mucositis
Otitis Media
Reactive Airway Disease

DNA-Nucleotide Immunotherapy & The Use of Microdose DNA:

The New Frontier Has Begun
The characterization of deoxyribonucleic acid, or DNA, by James Watson and Francis Crick in 1953 (Nobel Prize, 1962) ranks as one of the great scientific achievements of the 20th century. This was the focal point for the burgeoning field of molecular biology, which is the study of molecules that constitute the life process.

Research in this area has exploded in the last fifty years. DNA codifies, in its nucleotide sequences, the codes of life, which are at the core of our molecular origins of life and its progression. The Human Genome Project, which determined the exact sequence of the human genome, will have great impact for many decades and centuries to come in the areas of health, life span, politics and procreation. In many ways our genetics determine much of who we are and how we are. Synthetic Stimulatory DNA

There is a newly discovered regulatory use of synthetic stimulatory DNA as a signaling molecule. We will start with a concise literature review of published literature which focuses on the use of a single sequence of synthetic DNA composed of guanine and cytosine, that has been shown to exert a profound effect on immunity, allergy, and inflammation. This synthetic DNA is being intensively studied for use as a vaccine, an immunotherapy and much more. It appears to be generally safe, fast-acting and dramatic. However, more research will be required for its full development as an FDA-approved DNA drug. Millions have already been spent and dozens of researchers are involved.

Natural Microdose DNA (Mucolyxir)
Some medical and veterinary doctors have been pioneering the use of microdose DNA (Mucolyxir) from natural sources for a variety of respiratory health conditions. The modality has been used to treat respiratory ailments in dogs, cats and horses, as well as in infants, children, and adults. The observations from a number of these doctors also indicate that we are entering a new area of natural microdose DNA (Mucolyxir)-based therapeutics.

For more on natural microdose DNA (Mucolyxir), read the presentation from Dr. Allan Lieberman, M.D., as well as interviews with Dr. Ken Unice, D.O. and Dr. Jerry Dorsam, D.V.M..

back to top

The Dawn of the New DNA Era

The immunostimulatory effects of bacterial extracts, and its application to host defense have been studied for over 100 years. In the last 10 years, it has been determined that unmethylated nucleotides derived from bacterial DNA are responsible for the observed beneficial immune effects. Much of this research has been performed with a specific, patented sequence of nucleotides, CpG DNA. This form of synthetic DNA has been shown to stimulate the immune system, as well as being anti-inflammatory. A partial summary of findings below are taken from review of over thirty sophisticated research publications and associated with dozens of different researchers. Their work, through in vitro studies and animal and human research, shows the enormous therapeutic potential of synthetic stimulatory DNA.

Based on this body of research with respect to immunological and inflammatory modulation, synthetic DNA sequences have been found to:

* Balance and enhance the immune response via normalization of cytokine ratios.1 In ailments such as asthma and allergies that affect the respiratory tract, the ratio of type-1 and type-2 T-helper cells (Th1/Th2 ratio) is altered. Specifically, the Th2 immune response is enhanced, while the Th1 immune response may be suppressed, leading to unfavorable alterations in cytokine balances that favor the disease state. CpG DNA beneficially reduces the Th2 response and enhances the Th1 response to restore homeostasis.

Reduce inflammation associated with asthma and allergic respiratory diseases.2
Reduce lung damage and ‘remodeling’ due to allergic stress.3
Increase CD8 cytotoxic T Cell lymphocyte response, which enhances immunity.4
Treat allergic rhinitis in mice (reduced inflammatory mediators).5
Attenuate the magnitude of airway hyper-reactivity and airway remodeling in non-human primates with experimentally induced allergic airways diseases.6
Stimulate an important pathway for the development of CD*(+) cytotoxic T lymphocyte responses against infectious pathogens.7
Synthetic DNA-based vaccines (antigens prepared with DNA-specific sequences) have been created for treatment of allergic, infectious and other respiratory ailments.8 When tested in humans, these demonstrated great potential for a safe form of allergen-specific immunotherapy.9 These agents also may be used to create effective vaccines against infective pathogens.10 Antiviral actions have been attributed to the ability of synthetic DNA sequences to induce type 1 interferons.11 A DNA G vaccine significantly inhibited RSV (respiratory syncytial virus), viral replication, mucus expression, and importantly, was associated with inhibition of RSV-induced airways responsiveness.12

To provide just one recent, specific example regarding the use of synthetic DNA to treat respiratory ailments, consider the recent manuscript by Dr. Eyal Raz and his research team from the Respiratory Biology and Medicine Department of the University of California at Davis, and School of Medicine, University of California, San Diego. Dr. Raz was one of the original researchers to utilize synthetic DNA as an immune signaling molecule. The research team found that inhaled immunostimulatory oligonucleotides can attenuate the magnitude of airway hyperactivity and airway remodeling produced in primates with experimentally induced airway disease. The nucleotide sequence that was used, characteristic of bacterial DNA, was believed to be rapidly detected by vertebrate innate immune receptors, including those on dendritic cells, macrophages, monocytes and neutrophils. The sequence (delivered mucosally or systemically) had previously been shown to inhibit airway remodeling and airway hyper-responsiveness in rodents. The present study relied on a primate model of allergic asthma using aerosolized dust mite antigen. The model exhibited the hallmarks of allergic asthma. Airways from nucleotide-treated monkeys had thinner basement membranes, fewer mucus cells, fewer eosinophils and fewer mast cells than controls.

The beneficial applications of synthetic DNA are by no means limited to respiratory diseases. For example, synthetic DNA can ameliorate experimental and spontaneous murine colitis.13 These findings suggest a physiologic anti-inflammatory role for synthetic DNA in the GI tract.14 In one related study, it was concluded that the protective effects of probiotics are mediated by their own DNA, rather than by either metabolites of the probiotics or by their ability to colonize in the colon.14 Natural Microdose DNA (Mucolyxir) as an Alternative to Synthetic DNA

As an alternative to synthetic DNA, a number of clinical investigators have been studying the use of a proprietary formulation of natural microdose DNA (Mucolyxir) from mammalian or other eukaryotic sources for its use for patients with allergies and other respiratory conditions. The use of this natural microdose DNA (Mucolyxir) comes as a surprise in that the clinical effect is impressive, and yet the therapeutic agent is used in the LOW microgram level. This is reminiscent of both homeopathy, where very low dose agents are used, and low dose neutralization therapy, which is often used for allergies and hypersensitivities.

back to top

AAEM Allan Lieberman, M.D. on Natural Microdose DNA (Mucolyxir)
AAEM Presentation, October 2004, Hilton Head, South Carolina

About ten years ago one of my patients who had cystic fibrosis called and told me that the product which he was using every morning, in order to help clean out his lungs, Pulmozyme, cost $13,000 a year. I was so infuriated that I called a colleague of mine and complained to him and he said to me, “Well Lieberman, if they are using DNAse*, what should we use?” Then suddenly he said, “If they are using DNAse, why don’t we use DNA.” Now what you need to know is that the logic of using DNAse was that in cystic fibrosis, a lot of that phlegm and exudate, which is infiltrating the lungs in the airway of all of these patients, is made up of a massive amount of white blood cells and their debris, which is extremely high in DNA. So that’s why they use the DNAse. So that was their logic, but what I said to my colleague was, “How did you arrive at DNA?” and he said, “I don’t know, it just sounds right.” We went out and found two or three sources of DNA and we tried it. I was fortunate enough to have twins, in their mid-twenties who had cystic fibrosis that volunteered to try these DNA drops sublingually and by God, it really worked. It had incredible expectorant action, the mucus just kept coming up so incredibly thin that we had to learn very quickly to be careful that we don’t drown these patients. They improved their pulmonary function. They gained weight for the first time in years, so much so that they had to go out and buy new clothes to fit their new bodies, and they did not have to be hospitalized for the first time in years because of their disease. So based upon this initial study, we went out and looked for other cystic fibrosis patients. Over time, we accumulated enough cases for a pilot study to see that what we were doing was really working. After the successes with the microdose DNA (Mucolyxir) with cystic fibrosis, we wondered if it would also help patients with bronchitis, asthma, and COPD. We were amazed to find that in the few cases that we tried, that it too worked, and the most amazing thing was it didn’t have any side effects. Based upon these preliminary studies, we were ready for a Proof of Concept Trial for chronic bronchitis and COPD. We hired a clinical research organization who did a study on 100 patients with these diseases. In the bronchitis study, the summary was: In patients with wet cough, sputum production, and impaired pulmonary function, which was a measure of forced expiratory volume in one second of about 65%, the DNA demonstrated increased sputum production and ease of expectoration. There was a very definite improvement in the symptoms of chronic bronchitis including ease of breathing. People were able to sleep through the night without coughing. There was significant improvement with walking and working. Objectively, there was improved pulmonary function, most notably on small airway flow, the FEV 25/75 fraction and by improved overall quality of life. The more important thing about this was it’s excellent safety profile. There was no question that there was a very statistically significant difference between the active and placebo groups.

We looked at the COPD patients characterized by dry cough, little or no sputum production, and severely impaired pulmonary function, where their forced expiratory volume was in the vicinity of about 25% and with evidence of non-reversible disease. The microdose DNA (Mucolyxir) demonstrated increased sputum production with improvement in COPD symptoms, especially shortness of breath. There was obvious improvement in forced expiratory volume, and also in the carbon monoxide co-efficient of diffusion. There was significant increase in distance traveled during 6 minute walks, and a corresponding increase in their oxygenation, and again, with an excellent safety profile. After over ten years of working with microdose DNA in hundreds of patients on thousands of doses, it became apparent that there were other indications for its use. It was especially valuable in acute and chronic sinusitis, and in acute and chronic otitis media. Obstruction is often the pre-requisite of infection, so it should have come as no surprise to us that microdose DNA would also excel in chronic sinusitis and otitis media. Patients with chronic sinusitis would refuse literally to come off the microdose DNA (Mucolyxir) once we had put them on it because they felt so much better.

We could pause here for just a second and ask ourselves – what’s the mechanism of action of microdose DNA (Mucolyxir), and how does it do the things we are seeing? Unequivocally, it has terrific decongestive and liquefying properties for tenacious secretions from the upper and lower airway. It also seemed to have an anti-allergy effect. When we take infants and children that are impossible to test in the office because of their size and because of their rambunctiousness, we use the DNA. We use one drop sublingually four times a day, and we find for example, that a lot of their allergic signs and symptoms literally are controlled with DNA. It also seems to have an incredibly wonderful property of reducing swelling and obstruction.

We call this treatment signal therapy. It represents a whole new concept in medicine using natural products to signal the body’s regulatory systems – the nervous system, the immune system, and the endocrine system. As regulatory systems, what they’re really doing is up-regulating and down-regulating to induce homeostasis. I tell my patients that the signal is like a conductor of a symphony who stands in front of a 120-piece orchestra, and when he raises his baton and it goes down, they all play at the same time. The question of course is how does the body know whether it should up-regulate or down-regulate something. And I honestly tell them that I haven’t the foggiest idea of how the body knows to do it. The only thing I know when using this for over ten years, is it always does it right.

I’ve saved the best for last because I’d like to tell you a little bit about an experience with microdose DNA (Mucolyxir) with a patient with acute and chronic otitis media. One day I was evaluating a child for ADHD. There was a terrible smell in the room and it soon became apparent that he had parulent exudate pouring out of his ear. He had a chronic otitis media, which had been there for months. The mother couldn’t clear it up. So that night I put him on microdose DNA and by morning, the exudate had reduced dramatically, and this time I looked and saw that the perforation, which was quite large initially, looked to me to be about half the size in just twelve hours. The mom called back and told me that in two and a half to three weeks, the perforation was totally closed and the exudate was gone.

In clinical trials with over 100 infants and children with acute otitis media, what we found is that 80-90% of these children respond on microdose DNA (Mucolyxir). What we do at the very first sign of a cold or an ear infection is start with a drop under their tongue every 10-15 minutes for 4 doses, and a drop every one to two hours thereafter until the crying and pain subsides, and then four times daily until the infection is over. The medical literature is pretty clear that in the treatment of otitis media there are really no benefits in the use of antibiotics. But I could tell you as a pediatrician, or as an ex-pediatrician, that it is difficult to not want to use an antibiotic. We now have an agent which is extremely valuable in helping these patients.

I have used natural microdose DNA (Mucolyxir) for ten years with hundreds of patients and thousands of doses. Every patient or household should have a bottle on hand for respiratory support and other uses as indicated.

back to top

Interview – Ken Unice, D.O. on Natural Microdose DNA (Mucolyxir), October 12, 2004

What do you use it for in your patients?

Dr. Unice: I’ve used natural microdose DNA (Mucolyxir) in acute otitis media, especially in children, acute sinusitis, and acute bronchitis. I have used it in chronic bronchitis, reactive airways disease, emphysema, and mucositis.

What do you have the most experience with?

Dr. Unice: Probably upper respiratory, including sinusitis and bronchitis.

Does it work well?

Dr. Unice: Yes, I’ve had good success with it.

If they had an infection wouldn’t they need an antibiotic?

Dr. Unice: Well, first of all with acute sinusitis and acute bronchitis, many of these are viral and there is no effective treatment. The good thing about microdose DNA is that it works for both viral and non-viral, or bacterial infections. That’s a big plus because as it is now, there’s a tremendous overuse of antibiotics.

So in the viral form does it just ease the stress until the body repairs itself?

Dr. Unice: No, you see results within hours the first day. You are doing something acutely, more than just giving the body time to fight the infection. In the bacterial form, even without antibiotics, you see it to be effective?

Dr. Unice: Yes, this is successful in both. It’s difficult to prove because we don’t often look at samples of the fluid. But I would say those that appear to be bacterial respond well.

So, percentage-wise is there a sense of how well it works?

Dr. Unice: I would probably say 70-80%.

What about the efficacy regarding otitis media?

Dr. Unice: Well, I think the important thing is the relatively quick pain relief in the first three hours. There’s improvement in fever, irritability, and activity level, and the response is very quick and as I said, on the first day. Many of these children especially, will sleep the first night without pain, without waking up. And it reduces analgesic medication substantially. The good thing about it also, is that otitis has many origins including viral and bacterial and it seems to be effective in both types.

Any adverse effects with any of this?

Dr. Unice: I’ve never really seen any side effects. I’ve used it since 1998. I think the other point that you can make though, is there’s a big trend these days to move away from antibiotic therapy. In some countries, especially in Europe, these infections aren’t treated necessarily with antibiotics. However, the children are still much impacted by the infection. Also, we can help improve these situations without increasing antibiotic resistance, which is very important these days.

And that’s a good point, so what do you think it’s doing? How do you think it’s working?

Dr. Unice: I don’t know. I’d like to think of it as improving the drainage and mucus movement of the sinuses, and bronchial tree, and the middle ear. The response is fairly quick though, and there may be other mechanisms that are active here, like a thinning of mucus. Another use is for mucositis, which is a complication after radiation treatment for oral pharyngal cancer.

So what happens there?

Dr. Unice: A thick mucus is produced in the throat. It doesn’t cure it, but it does improve the mucus, causing significant thinning.

Have you yourself had experience with COPD?

Dr. Unice: Yes, I’ve used it on many occasions. And there was an improvement in breathing and shortness of breath as well.

So I guess that’s what the trials were on, the COPD?

Dr. Unice: Yes. And one of the things that might be important here is the DNA seems to effect a wide percentage of the population, suggesting more of a universal application. It doesn’t have to be as selective to the patient, the dose is uniform as well, which is a good thing.

So, selective in the type of therapy given?

Dr. Unice: Yes. With antibiotics, you may have to gear it for specific bacteria. But this seems to be effective across a wide range with the same material, the same molecule. And I think that’s important. Also the duration of treatment is shorter. Usually it is 5-7 days or less.

back to top

Interview – Jerry Dorsam, D.V.M. on Natural Microdose DNA (Mucolyxir), October 14, 2004

Dr. Dorsam: In terms of applications, our clinical case load changed due to the local humane society – we were seeing a lot of their puppies and kittens that were trying to be adopted. They were coming in with really massive and severe respiratory diseases. Characterized by sneezing, runny eyes, runny nose, fevers, not eating, depression, and listlessness – the whole nine yards. And the conventional thought has always been to treat these guys with antibiotics just because there really isn’t anything else out there. And of course, a significant majority of these cases are indeed NOT bacterial. But are indeed viral, therefore, in the perfect environment, the antibiotic is not going to be of any help. So I started using the natural microdose DNA (Mucolyxir). We saw probably a predominant number of kittens and we noted, they’d come in with fevers, and we noted that after the third dose or eighteen hours, after the onset of therapy, they were completely normal. And that was something that really surprised us because we saw such an early response so quickly, and that was the end of it.

Has any other medicine you used at the clinic been effective for these types of conditions?

Dr. Dorsam: No, not even close. I mean, you can see some improvement with antipyretics, bringing their temperatures down and making them feel better. But nothing stops the discharge or the sneezing or the clinical symptoms like the DNA. I mean these kittens were pretty much on their way. And no other therapy was given, no antibiotics, no things to control fever, so we started using the DNA and found that we could almost wipe out an infection in most of these kittens. Now there were those occasional ones that would drag on, but our opinion was, and still is, that for the DNA, probably the very best indication is to use it very early on in respiratory disease. If you wait until these guys are sick, three to ten days down the line, or even longer, the DNA is going to have moderate improvement. If you catch a kitten or puppy at the outset of very early symptoms, you’ll often times have a very positive outcome.

If you do catch it early, how many of the patients respond percentage wise?

Dr. Dorsam: Oh, almost 100% of them. A statistically significant majority will respond almost within the first 36 to 48 hours. In very, very few of them, you won’t see some improvement.

Have you ever used it for a bacterial infection?

Dr. Dorsam: Because we’re not a laboratory where we test the fluids, we don’t know. We were treating these guys so they could be adopted. We were purely using it compassionately to get them better. Probably, if you talk to people in the SPCA environment, and they’ve had a chance to culture many of these nasal membranes and conjunctival membranes, they’ll tell you that a lot of these guys are suffering from bacterial infections. That it isn’t a pure viral epidemic that you see. So it’s very difficult without having actually done culture studies to figure out who’s got what and what’s the percentage of that virus versus that bacteria versus the combination, etc. So, I don’t know. But it helps. If I’m presented with a case of respiratory disease in a young kitten or puppy and I catch it early I’m going to treat it with the DNA and know that I’m going to make that particular individual feel a lot better in a very short time.

Have you noticed any adverse effects?

Dr. Dorsam: No, none, absolutely none. In fact I have a client who runs a rescue agency. She’s been part of the Humane Society here in Charleston for 25 years and she got fed up with the buraeucracy so she started her own feline and canine rescue and fostering. And she’ll come and get 100 cc’s of the DNA. She uses it and is very well pleased, in fact there are so many people down the chain that use it that know that it has these benefits so, it works very well.

How would you speculate that it’s working, what do you think it does?

Dr. Dorsam: Well, it has been suggested that it may stimulate the dendritic cells in the mucosa and may serve as a number of different things stimulating DNA and what not. I don’t really know what it’s actually doing in the mucosa because it’s given orally and it’s absorbed through the oral mucosa, so it’s not really something that you’re nebulizing. It’s going sublingually into the animal.

Is there anything you’d like to add about the DNA?

Dr. Dorsam: No, I can only tell you what my experience is. I’ve used it primarily in that instance. I know third-hand that it was used as a coughing model or for treating coughing horses. But if you talk to people who have used it in terms of respiratory disease in the horse, again this is third-hand and I can’t comment directly, is that it’s helped them.

Would you use the same dose for a kitty as a horse?

Dr. Dorsam: Yes but that’s only what I’ve been told. And, we just give 0.2 cc’s 2-3x per day sublingually.

back to top

Editor’s Note on Natural Microdose DNA (Mucolyxir)

Dr. Allan Lieberman, a 25-year member of AAEM, refers to the DNA effect as a ‘signaling’ effect, and the use of natural microdose DNA here as a signaling molecule.

Similar results were found in clinical use in horses and dogs suffering from respiratory disorders. The animals could breathe easier and exercise more as a result of using the microdose DNA.

Dr. Jerry Dorsam, DVM also used this for puppies and kittens from his local SPCA that were ‘waiting for adoption’, but were suffering from massive and severe respiratory conditions including sneezing, runny eyes, runny nose, fever and depression.

Dr. Kenneth Unice, DO, a physician in private practice says that his otitis media patients usually respond very quickly. In the first few days there is an improvement in fever and irritability. “Many of these children will sleep the first night without pain and without waking up, and their use of analgesic medicine diminishes substantially.”

Dr. Albert Dahlberg, M.D., Ph.D., a professor at Brown University, says that natural microdose DNA is different than other DNA-based therapies.

“This approach does not effect gene transfer; it relies on the physical molecule itself to place into motion a series of events at the cellular level”. Dr. Dahlberg has determined that the nucleotide sequence doesn’t matter. Different animal sources of DNA were tested and found to work the same. Dr. Dahlberg created synthetic DNA with only adenine and thymine and it also appeared to produce the same results. So in opposition to the stated supposition of the published work, DNA can provide a general signal which may be related to the component nucleotides, but not necessarily their sequence. This is not to detract from the impressive body of work published by many scientists in dozens of publications. And we do not suggest that nonspecific microdose DNA application is the same as the heavily researched bacterial sequence DNA. However, there appear to be striking similarities.

The safety of this microdose DNA (Mucolyxir) and lack of side effects is noteworthy. In both the published animal and human studies and in the clinical studies with nonspecific DNA sequences, the safety and lack of side effects appears to be consistent. There is much less than a gene’s worth of DNA in each dose of microdose DNA and therefore does not have any coding potential. “It appears to rely on harmonizing the body’s own regulatory systems.” What is particularly surprising is that a single dose ‘fits all’, and not only in humans. From interviews of doctors using natural microdose DNA (Mucolyxir), the same general dosages a few times a day works for kittens, puppies and horses, as well as for infants, children, and adults. So there is apparently quite a large range of dosages from which these benefits may generate. Increasing the dosage does make a difference to some in terms of achieving greater benefit. For others, the process may be too fast and they reduce the number of drops accordingly.

From the studies and clinical work cited here, we are just seeing the ‘tip of the iceberg’ with these signaling regulatory DNA. It is likely that the reports of therapeutic benefit from oral DNA supplements may be related to the mechanisms and observations discussed here.

The microdose DNA appears to stimulate P2Y receptors on epithelial cells that line the respiratory tract and ear canal. P2Y stimulation then causes the cilia to beat faster and stronger, which in turn enhances mucus movement leading to drainage, expectoration, etc., and thus altering, or disrupting that habitat so favored by infectious agents. That is to say, DNA may likely have no direct anti-bacterial or anti-viral effect, but rather, have a direct action on mucus itself in that those agents no longer find the ear canal or respiratory tract to be favorable habitats.

The observations presented here also suggest that there is a whole different population of molecules in the body that represent unique therapeutic targets for intervention with other innovative ‘nanotechnology’ approaches. These appear to represent very safe pathways to intersect with. (Personal communications with A. Leiberman and L. Kaplan).

Presently I am aware of a number of other natural agents used in microdoses that are being explored for a variety of interesting benefits including COBAT (carbobenzoxy beta-alanyl taurine), a dipeptide used in nanogram levels for reversing fatigue in various fatigue-causing conditions.

I am often both stunned and thrilled by the novelty and utility that I come across as I investigate issues in nutritional medicine. The modality of natural microdose DNA clearly reflects to me how living bodies seem to seek to establish health and homeostasis. In this case, the stimulant is just a tiny bit of DNA.

back to top

Cited References
(from “The Dawn of the New DNA Era”)

1. Chu W, Gong X, Li Z, et al. DNA-PKcs is required for activation of innate immunity by immunostimulatory DNA. Cell. 2000 Dec 8;103(6):909-18.

2. Ikeda RK, Nayar J, Cho JY, et al. Resolution of airway inflammation following ovalbumin inhalation: comparison of ISS DNA and corticosteroids. Am J Respir Cell Mol Biol.2003 Jun;28(6):645-7.

3. Youn CJ, Miller M, Baek KJ, et al. Immunostimulatory DNA reverses established allergen-induced airway remodeling. J Immunol, 2004 Dec 15;173(12):7556-64.

4. Datta SK, Cho HJ, Takabayashi K, et al. Antigen-immunostimulatory oligonucleotide conjugates: mechanisms and applications. Immunol Rev. 2004 Jun;199:217-26.

5. Rhee CS, Libet L, Chisholm D, et al. Allergen-independent immunostimulatory sequence oligodeoxynucleotide therapy attenuates experimental allergic rhinitis. Springer Semin Immunopathol. 2004 Oct 14.

6. Michelle V. Fanucchi, Edward S. Schelegle, Gregory L. Baker, et al. Immunostimulatory Oligonucleotides Attenuate Airways Remodeling in Allergic Monkeys. American Journal of Respiratory and Critical Care Medicine, Vol 170:1153-1157.

7. Datta SK, Raz E. Induction of antigen cross-presentation by Toll-like receptors. Springer Semin Immunopathol. 2005 Jan;26(3):247-55. Epub 2004 Oct 14.

8. Datta SK, Cho HJ, Takabayashi K, et al. Antigen-immunostimulatory oligonucleotide conjugates: mechanisms and applications. Immunol Rev. 2004 Jun;199:217-26.

9. Spiegelberg HL, Horner AA, Takabayashi K, Raz E. Allergen-immunostimulatory oligodeoxynucleotide conjugate: a novel allergoid for immunotherapy. Curr Opin Allergy Clin Immunol. 2002 Dec;2(6):547-51.

10. Horner AA, Ronaghy A, Cheng PM, et al. Immunostimulatory DNA is a potent mucosal adjuvant. Cell Immunol. 1998 Nov 25;190(1):77-82.

11. Lee J, Chuang TH, Redecke V, et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci USA. 2003 May 27;100(11):6646-51. Epub 2003 May 08.

12. Miller M, Cho JY, Beak KJ, et al. Plasmid DNA encoding the respiratory syncytial virus G protein protects against RSV-induced airway hyperresponsiveness. Vaccine. 2002 Jul 26; 20(23-24):3023-33.

13. Rachmilewitz D., Karmeli F, Takabayashi K, et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology. 2002 May;122(5):1428-41.

14. Rachmilewitz D, Katakura K, Karmeli F, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology. 2004 Feb;126(2):520-8.

back to top

Additional References

Kobayashi H, Horner AA, Takabayashi K, Nguyen MD, Huang E, Cinman N, Raz E. Immunostimulatory DNA pre-priming: a novel approach for prolonged Th1-biased immunity. Cell Immunol. 1999 Nov 25;198(1):69-75.

Van Uden J, Raz E. Immunostimulatory DNA and applications to allergic disease. J Allergy Clin Immunol. 1999 Nov;104(5):902-10.

Spiegelberg HL, Raz E. DNA vaccines. Allergy. 1999;54 Suppl 56:47-8.

Martin-Orozco E, Kobayashi H, Van Uden J, Nguyen MD, Kornbluth RS, Raz E. Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences.Int Immunol. 1999 Jul;11(7):1111-8.

Broide D, Raz E. DNA-Based immunization for asthma. Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):453-6.

Spiegelberg HL, Broide D, Tighe H, Roman M, Raz E. Inhibition of allergic inflammation in the lung by plasmid DNA allergen immunization. Pediatr Pulmonol Suppl. 1999;18:118-21.

Broide D, Schwarze J, Tighe H, Gifford T, Nguyen MD, Malek S, Van Uden J, Martin-Orozco E, Gelfand EW, Raz E. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol. 1998 Dec 15;161(12):7054-62.

Spiegelberg HL, Tighe H, Roman M, Broide D, Raz E. Inhibition of IgE formation and allergic inflammation by allergen gene immunization and by CpG motif immunostimulatory oligodeoxynucleotides. Allergy, 1998;53(45 Suppl):93-7.

Goodman JS, Van Uden JH, Kobayashi H, Broide D, Raz E. DNA immunotherapeutics: new potential treatment modalities for allergic disease. Int Arch Allergy Immunol. 1998 Jul;116(3):177-87.

Tighe H, Corr M, Roman M, Raz E. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol Today. 1998 Feb;19(2):89-97.

Carson DA, Raz E. Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. J Exp Med. 1997 Nov 17;186(10):1621-2.

Roman M, Spiegelberg HL, Broide D, Raz E. Gene immunization for allergic disorders. Springer Semin Immunopathol. 1997;19(2):223-32.

Spiegelberg HL, Orozco EM, Roman M, Raz E. DNA immunization: a novel approach to allergen-specific immunotherapy. Allergy. 1997 Oct;52(10):964-70.

Goodman JS, Raz E. Circling back to gene vaccines. Gastroenterology. 1997 Nov;113(5):1812-4.

Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A, Kornbluth RS, Richman DD, Carson DA, Raz E. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med. 1997 Aug;3(8):849-54.

Lee DJ, Tighe H, Corr M, Roman M, Carson DA, Spiegelberg HL, Raz E. Inhibition of IgE antibody formation by plasmid DNA immunization is mediated by both CD4+ and CD8+ T cells. Int Arch Allergy Immunol. 1997 May-Jul;113(1-3):227-30.

Sato Y, Roman M, Tighe H, Lee D, Corr M, Nguyen MD, Silverman GJ, Lotz M, Carson DA, Raz E. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science. 1996 Jul 19;273(5273):352-4.

Raz E, Tighe H, Sato Y, Corr M, Dudler JA, Roman M, Swain SL, Spiegelberg HL, Carson DA. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci U S A. 1996 May 14;93(10):5141-5.

Raz E, Ben-Bassat H, Davidi T, Shlomai Z, Eilat D. Cross-reactions of anti-DNA autoantibodies with cell surface proteins. Eur J Immunol. 1993 Feb;23(2):383-90.

Van Uden JH, Tran CH, Carson DA, Raz E. Type I interferon is required to mount an adaptive response to immunostimulatory DNA. Eur J Immunol. 2001 Nov;31(11):3281-90.

Broide DH, Stachnick G, Castaneda D, Nayar J, Miller M, Cho J, Rodriquez M, Roman M, Raz E. Immunostimulatory DNA mediates inhibition of eosinophilic inflammation and airway hyperreactivity independent of natural killer cells in vivo. J Allergy Clin Immunol. 2001 Nov;108(5):759-63.

Cho JY, Miller M, Baek KJ, Castaneda D, Nayar J, Roman M, Raz E, Broide DH. Immunostimulatory DNA sequences inhibit respiratory syncytial viral load, airway inflammation, and mucus secretion. J Allergy Clin Immunol. 2001 Nov;108(5):697-702.

Hayashi T, Rao SP, Takabayashi K, Van Uden JH, Kornbluth RS, Baird SM, Taylor MW, Carson DA, Catanzaro A, Raz E. Enhancement of innate immunity against Mycobacterium avium infection by immunostimulatory DNA is mediated by indoleamine 2,3-dioxygenase. Infect Immun. 2001 Oct;69(10):6156-64.

Horner AA, Widhopf GF, Burger JA, Takabayashi K, Cinman N, Ronaghy A, Spiegelberg HL, Raz E. Immunostimulatory DNA inhibits IL-4-dependent IgE synthesis by human B cells. J Allergy Clin Immunol. 2001 Sep;108(3):417-23.

Uchijima M, Raz E, Carson DA, Nagata T, Koide Y. Identification of immunostimulatory DNA-induced genes by suppression subtractive hybridization. Biochem Biophys Res Commun. 2001 Aug 31;286(4):688-91.

Spiegelberg HL, Raz E. DNA based immunotherapeutics for allergy. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 1999;(93):283-90; discussion 291-2.

Horner AA, Datta SK, Takabayashi K, Belyakov IM, Hayashi T, Cinman N, Nguyen MD, Van Uden JH, Berzofsky JA, Richman DD, Raz E. Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites. J Immunol. 2001 Aug 1;167(3):1584-91.

Broide DH, Stachnick G, Castaneda D, Nayar J, Miller M, Cho JY, Roman M, Zubeldia J, Hayashi T, Raz E. Systemic administration of immunostimulatory DNA sequences mediates reversible inhibition of Th2 responses in a mouse model of asthma. J Clin Immunol. 2001 May;21(3):175-82.

Ayash-Rashkovsky M, Weisman Z, Zlotnikov S, Raz E, Bentwich Z, Borkow G. Induction of antigen-specific Th1-biased immune responses by plasmid DNA in schistosoma-infected mice with a preexistent dominant Th2 immune profile. Biochem Biophys Res Commun. 2001 Apr 20;282(5):1169-76.

back to top

AAEM Allan Lieberman, M.D. on Natural Microdose DNA (MucolyxirInterview – Ken Unice, D.O. on Natural Microdose DNA (MucolyxirInterview – Jerry Dorsam, D.V.M. on Natural Microdose DNA (MucolyxirEditor’s Note on Natural Microdose DNA (Mucolyxir)

AAEM Allan Lieberman, M.D. on Natural Microdose DNA (MucolyxirInterview – Ken Unice, D.O. on Natural Microdose DNA (MucolyxirInterview – Jerry Dorsam, D.V.M. on Natural Microdose DNA (MucolyxirEditor’s Note on Natural Microdose DNA (Mucolyxir)

    

Home | Books & Tapes | Nutrition Notebook | Our Privacy Policy | Contacts

Springboard products which are foods and/or foods for special dietary use, are not offered for the
diagnosis, cure, mitigation, treatment, or prevention of any disease or disorder nor have any statements herein been evaluated by
the Food and Drug Administration. We strongly encourage you to discuss topics of concern with your health care professional.

Copyright © 1998-2007 Springboard All rights reserved.

WebSite Designed and Managed by
AllBusNet.com
a subsidiary of Aerial Dynamics

http://www.springboard4health.com/store/more_arg_mucolyxir.html

| | | | Springboard products which are foods and/or foods for special dietary use, are not offered for thediagnosis, cure, mitigation, treatment, or prevention of any disease or disorder nor have any statements herein been evaluated bythe Food and Drug Administration. We strongly encourage you to discuss topics of concern with your health care professional.Copyright © 1998-2007 Springboard All rights reserved.WebSite Designed and Managed by a subsidiary of Aerial Dynamics

 

Leave a Reply

*